Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT04931173 |
Other study ID # |
PJT-165836 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
January 2024 |
Est. completion date |
March 2026 |
Study information
Verified date |
October 2023 |
Source |
Mount Sinai Hospital, Canada |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Following colon surgery, surgical site infection (SSI) is the most common complication and
leads to longer recovery time for patients and increased health care costs. Currently, there
is high quality evidence to show that the combination of intravenous antibiotics (IVA),
mechanical bowel preparation (MBP) and oral antibiotics (OA) is the most effective bowel
preparation to reduce SSI. However, there are no studies comparing IVA+MBP+OA and IVA+OA.
This is an important question because if IVA+OA works the same as IVA+MBP+OA, then MBP may be
safely omitted as part of the bowel preparation to reduce SSI and patients would avoid the
side effects of MBP prior to their surgery. Therefore, the objective is to perform a trial to
determine if IVA+OA works the same as IVA+MBP+OA to reduce SSI following colon surgery.
Description:
Background: Colon surgery includes surgery for colon cancer, inflammatory bowel disease and
other benign disease such as diverticulitis. In Canada, approximately 21,000 colon surgeries
are performed annually. Following colon surgery, the most common complication is surgical
site infection (SSI) and rates of up to 25% have been reported. The high volume of colon
cancer surgery, coupled with high rates of SSI lead to considerably worse health care
outcomes for patients including increased recovery time, length of stay and readmission.
Currently, several different bowel preparations to reduce SSI are being used in Canada and
there is significant practice variation due to lack of RCTs and conflicting practice
guidelines. More recently, several large observational studies and a network meta-analysis
have shown that a combination of intravenous antibiotics, mechanical bowel preparation and
oral antibiotics (IVA+MBP+OA) is superior to IVA+MBP and IVA alone. Interestingly, these
studies also showed that SSI rates for IVA+OA are comparable to IVA+MBP+OA. These data
provide a strong rationale to conduct a RCT comparing IVA+OA versus IVA+MBP+OA to determine
if MBP is a necessary part of the bowel preparation or if MBP can be safely omitted and the
side effects of MBP avoided.
Objectives: Therefore, the objectives are to conduct a multi-centre, parallel, two arm,
non-inferiority RCT comparing IVA+MBP+OA versus IVA+OA to reduce SSI following colon surgery.
Methods: The inclusion criteria are any patient (i) undergoing elective colon surgery, (ii)
over the age of 18 years and (3) provides informed consent. Eligible patients at 4 centres
across Canada will be randomized to one of two groups: IVA+OA+MBP or IVA+OA. The primary
outcome for the trial is the overall rate of SSI at 30 days following surgery. Assuming an
overall SSI rate of 7% with IVA+MBP+OA and a non-inferiority margin of 4.0%, 1062 patients
will be required with a one sided alpha of 0.05 and a power of 80%. This non-inferiority
margin was unanimously accepted as clinically meaningful by all of the Site Leads at
participating centres. Primary analyses will be performed per-protocol in patients who
received treatment as allocated and underwent colon surgery. Overall SSI rates at 30 days
following surgery will be compared using a general linear model and non-inferiority will be
declared if the upper limit of the one sided 95% confidence interval of the absolute risk
difference of overall SSI following surgery does not include 4.0%.
Relevance: This trial will be highly relevant to both patients and physicians as the results
will provide definitive, high quality, patient-centred evidence about whether MBP is a
necessary part of the optimal bowel preparation to reduce SSI and improve both patient
experience and outcomes. These results will have significant potential to change practice in
Canada and world-wide.